{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T18:06:59Z","timestamp":1779300419583,"version":"3.51.4"},"reference-count":147,"publisher":"Elsevier","isbn-type":[{"value":"9780443432729","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.acr.2025.12.006","type":"book-chapter","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T20:50:34Z","timestamp":1768855834000},"page":"175-220","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in detection techniques regarding predictive, prognostic, and diagnostic biomarkers in solid cancers and its future challenges"],"prefix":"10.1016","author":[{"given":"Suryaprakash","family":"Tripathy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anmol","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manaswini","family":"Jagadeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishnu","family":"Swarup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj Mohan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudip","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj Kumar","family":"Jana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/bs.acr.2025.12.006_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-018-0058-3","article-title":"Early stage NSCLC \u2014 challenges to implementing ctDNA-based screening and MRD detection","volume":"15","author":"Abbosh","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"7655","key":"10.1016\/bs.acr.2025.12.006_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/bs.acr.2025.12.006_bib3","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/S1470-2045(12)70598-3","article-title":"Improvement of pathology in sub-Saharan Africa","volume":"14","author":"Adesina","year":"2013","journal-title":"The Lancet Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12672-025-02064-7","article-title":"AI-driven biomarker discovery: Enhancing precision in cancer diagnosis and prognosis","volume":"16","author":"Alum","year":"2025","journal-title":"Discover Oncology"},{"key":"10.1016\/bs.acr.2025.12.006_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2013.08.041","article-title":"Metabolomics in cancer biomarker discovery: Current trends and future perspectives","volume":"87","author":"Armitage","year":"2014","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"13","key":"10.1016\/bs.acr.2025.12.006_bib6","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: The PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/bs.acr.2025.12.006_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"6","key":"10.1016\/bs.acr.2025.12.006_bib8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1200\/JCO.2010.32.2685","article-title":"Adaptive clinical trials: The promise and the caution","volume":"29","author":"Berry","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbamcr.2015.10.022","article-title":"Characterization of the cell-free DNA released by cultured cancer cells","volume":"1863","author":"Bronkhorst","year":"2016","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12910-016-0162-9","article-title":"Dynamic consent: A potential solution to some of the challenges of modern biomedical research","volume":"18","author":"Budin-Lj\u00f8sne","year":"2017","journal-title":"BMC Medical Ethics"},{"issue":"21","key":"10.1016\/bs.acr.2025.12.006_bib11","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.acr.2025.12.006_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/gutjnl-2012-304149","article-title":"Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer","volume":"63","author":"Church","year":"2014","journal-title":"Gut"},{"issue":"6378","key":"10.1016\/bs.acr.2025.12.006_bib13","first-page":"926","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science (1979)"},{"issue":"5","key":"10.1016\/bs.acr.2025.12.006_bib14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/03007995.2022.2052513","article-title":"Clinical decision support system (CDSS) in primary care: From pragmatic use to the best approach to assess their benefit\/risk profile in clinical practice","volume":"38","author":"Cricelli","year":"2022","journal-title":"Current Medical Research and Opinion"},{"issue":"2","key":"10.1016\/bs.acr.2025.12.006_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumor heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"7274","key":"10.1016\/bs.acr.2025.12.006_bib16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"22","key":"10.1016\/bs.acr.2025.12.006_bib17","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/bs.acr.2025.12.006_bib18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"The Lancet Oncology"},{"issue":"45","key":"10.1016\/bs.acr.2025.12.006_bib19","doi-asserted-by":"crossref","first-page":"16368","DOI":"10.1073\/pnas.0507904102","article-title":"Detection and quantification of mutations in the plasma of patients with colorectal tumors","volume":"102","author":"Diehl","year":"2005","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"9","key":"10.1016\/bs.acr.2025.12.006_bib20","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-med-041316-085721","article-title":"Circulating tumor DNA: Measurement and clinical utility","volume":"69","author":"Donaldson","year":"2018","journal-title":"Annual Review of Medicine"},{"issue":"9","key":"10.1016\/bs.acr.2025.12.006_bib22","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.ejca.2007.03.021","article-title":"Tumor markers in colorectal cancer: European group on tumor markers (EGTM) guidelines for clinical use","volume":"43","author":"Duffy","year":"2007","journal-title":"European Journal of Cancer"},{"issue":"9793","key":"10.1016\/bs.acr.2025.12.006_bib23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2011","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41591-018-0316-z","article-title":"A guide to deep learning in healthcare","volume":"25","author":"Esteva","year":"2019","journal-title":"Nature Medicine"},{"issue":"7407","key":"10.1016\/bs.acr.2025.12.006_bib25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nature11251","article-title":"Non-invasive prenatal measurement of the fetal genome","volume":"487","author":"Fan","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.acr.2025.12.006_bib26","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jval.2012.05.006","article-title":"Challenges in the development and reimbursement of personalized medicine\u2014Payer and manufacturer perspectives and implications for health economics and outcomes research: A report of the ISPOR personalized medicine special interest Group","volume":"15","author":"Faulkner","year":"2012","journal-title":"Value in Health"},{"issue":"33","key":"10.1016\/bs.acr.2025.12.006_bib27","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1200\/JCO.19.03010","article-title":"Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National cancer institute molecular analysis for therapy choice (NCI-MATCH)","volume":"38","author":"Flaherty","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2025.12.006_bib28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11023-018-9482-5","article-title":"AI4People\u2014An ethical framework for a good AI society: Opportunities, risks, principles, and recommendations","volume":"28","author":"Floridi","year":"2018","journal-title":"Minds Mach (Dordr)"},{"issue":"8","key":"10.1016\/bs.acr.2025.12.006_bib29","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1592\/phco.28.8.992","article-title":"Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: Prevalence of related drug use","volume":"28","author":"Frueh","year":"2008","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"issue":"9","key":"10.1016\/bs.acr.2025.12.006_bib30","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nature Medicine"},{"issue":"7587","key":"10.1016\/bs.acr.2025.12.006_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nature16521","article-title":"Fully integrated wearable sensor arrays for multiplexed in situ perspiration analysis","volume":"529","author":"Gao","year":"2016","journal-title":"Nature"},{"issue":"302","key":"10.1016\/bs.acr.2025.12.006_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Science Translational Medicine"},{"issue":"21","key":"10.1016\/bs.acr.2025.12.006_bib33","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1016\/bs.acr.2025.12.006_bib34","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/bs.acr.2025.12.006_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"Gold","year":"2010","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/bs.acr.2025.12.006_bib36","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1373\/clinchem.2005.063289","article-title":"APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer","volume":"52","author":"Groskopf","year":"2006","journal-title":"Clinical Chemistry"},{"issue":"11","key":"10.1016\/bs.acr.2025.12.006_bib37","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/bs.acr.2025.12.006_bib38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.18383\/j.tom.2020.00013","article-title":"Intraobserver variability in bladder cancer treatment response assessment with and without computerized decision support","volume":"6","author":"Hadjiiski","year":"2020","journal-title":"Tomography"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13058-016-0753-x","article-title":"Plasma exosome microRNAs are indicative of breast cancer","volume":"18","author":"Hannafon","year":"2016","journal-title":"Breast Cancer Research"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biology"},{"issue":"20","key":"10.1016\/bs.acr.2025.12.006_bib41","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/jnci\/88.20.1456","article-title":"Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers","volume":"88","author":"Hayes","year":"1996","journal-title":"JNCI Journal of the National Cancer Institute"},{"issue":"2","key":"10.1016\/bs.acr.2025.12.006_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of\u00a0liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nature Reviews. Genetics"},{"issue":"22","key":"10.1016\/bs.acr.2025.12.006_bib43","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.acr.2025.12.006_bib44","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molonc.2012.01.010","article-title":"Cancer biomarkers","volume":"6","author":"Henry","year":"2012","journal-title":"Molecular Oncology"},{"issue":"5","key":"10.1016\/bs.acr.2025.12.006_bib45","first-page":"403","article-title":"Enhancing diversity to reduce health information disparities and build an evidence base for genomic medicine","volume":"15","author":"Hindorff","year":"2018","journal-title":"Permed (Medication)"},{"issue":"10048","key":"10.1016\/bs.acr.2025.12.006_bib46","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(16)31473-8","article-title":"New and emerging targeted treatments in advanced non-small-cell lung cancer","volume":"388","author":"Hirsch","year":"2016","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/bs.acr.2025.12.006_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/widm.1312","article-title":"Causability and explainability of artificial intelligence in medicine","volume":"9","author":"Holzinger","year":"2019","journal-title":"WIREs Data Mining and Knowledge Discovery"},{"issue":"13","key":"10.1016\/bs.acr.2025.12.006_bib48","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/bs.acr.2025.12.006_bib49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41568-018-0016-5","article-title":"Artificial intelligence in radiology","volume":"18","author":"Hosny","year":"2018","journal-title":"Nature Reviews. Cancer"},{"issue":"10\u201311","key":"10.1016\/bs.acr.2025.12.006_bib50","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.clinbiochem.2013.03.019","article-title":"miRNA in clinical practice: Pancreatic cancer","volume":"46","author":"Humeau","year":"2013","journal-title":"Clinical Biochemistry"},{"key":"10.1016\/bs.acr.2025.12.006_bib51","unstructured":"International ethical guidelines for health-related research involving humans. Geneva, Switzerland; 2016."},{"issue":"3","key":"10.1016\/bs.acr.2025.12.006_bib52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/emmm.201100209","article-title":"MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review","volume":"4","author":"Iorio","year":"2012","journal-title":"EMBO Molecular Medicine"},{"issue":"2","key":"10.1016\/bs.acr.2025.12.006_bib53","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/1535-7163.MCT-18-0535","article-title":"Genome-wide sequencing of cell-free DNA identifies copy-number alterations that can be used for monitoring response to immunotherapy in cancer patients","volume":"18","author":"Jensen","year":"2019","journal-title":"Molecular Cancer Therapeutics"},{"issue":"148","key":"10.1016\/bs.acr.2025.12.006_bib54","first-page":"167","article-title":"Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): An update","volume":"27","author":"Jonna","year":"2019","journal-title":"Discovery Medicine"},{"issue":"19","key":"10.1016\/bs.acr.2025.12.006_bib55","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-17-1439","article-title":"Hypermutated circulating tumor DNA: Correlation with response to checkpoint inhibitor\u2013based immunotherapy","volume":"23","author":"Khagi","year":"2017","journal-title":"Clinical Cancer Research"},{"issue":"17","key":"10.1016\/bs.acr.2025.12.006_bib56","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1016\/bs.acr.2025.12.006_bib57","doi-asserted-by":"crossref","first-page":"17442","DOI":"10.1074\/jbc.M110.107821","article-title":"Secretory mechanisms and intercellular transfer of MicroRNAs in living cells","volume":"285","author":"Kosaka","year":"2010","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/bs.acr.2025.12.006_bib58","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/annonc\/mdx765","article-title":"Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma","volume":"29","author":"Krug","year":"2018","journal-title":"Annals of Oncology"},{"issue":"6349","key":"10.1016\/bs.acr.2025.12.006_bib59","first-page":"409","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science (1979)"},{"issue":"3","key":"10.1016\/bs.acr.2025.12.006_bib60","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Research"},{"issue":"6","key":"10.1016\/bs.acr.2025.12.006_bib61","first-page":"411","article-title":"Establishment and its application of Chinese society of clinical oncology artificial intelligence system (CSCO AI)]","volume":"100","author":"Li","year":"2020","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"15","key":"10.1016\/bs.acr.2025.12.006_bib62","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/elps.201000598","article-title":"Proteomic identification of exosomal LRG1: A potential urinary biomarker for detecting NSCLC","volume":"32","author":"Li","year":"2011","journal-title":"Electrophoresis"},{"issue":"3","key":"10.1016\/bs.acr.2025.12.006_bib63","first-page":"683","article-title":"Combination of plasma microRNAs with serum CA19\u20109 for early detection of pancreatic cancer","volume":"131","author":"Liu","year":"2012","journal-title":"International Journal of"},{"issue":"6","key":"10.1016\/bs.acr.2025.12.006_bib64","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1016\/bs.acr.2025.12.006_bib65","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ijc.30752","article-title":"Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance","volume":"141","author":"Lobb","year":"2017","journal-title":"International Journal of Cancer"},{"issue":"4","key":"10.1016\/bs.acr.2025.12.006_bib66","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.juro.2014.10.121","article-title":"The prostate health index selectively identifies clinically significant prostate cancer","volume":"193","author":"Loeb","year":"2015","journal-title":"Journal of Urology"},{"issue":"20","key":"10.1016\/bs.acr.2025.12.006_bib67","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1158\/1078-0432.CCR-11-1244","article-title":"PTEN protein loss by immunostaining: Analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients","volume":"17","author":"Lotan","year":"2011","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.artmed.2014.06.004","article-title":"Recommendations for the ethical use and design of artificial intelligent care providers","volume":"62","author":"Luxton","year":"2014","journal-title":"Artificial Intelligence in Medicine"},{"issue":"21","key":"10.1016\/bs.acr.2025.12.006_bib69","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/bs.acr.2025.12.006_bib70","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S1470-2045(13)70008-1","article-title":"Paediatric cancer in low-income and middle-income countries","volume":"14","author":"Magrath","year":"2013","journal-title":"The Lancet Oncology"},{"issue":"3\u20134","key":"10.1016\/bs.acr.2025.12.006_bib71","first-page":"241","article-title":"Nuclear acids in human blood plasma","volume":"142","author":"Mandel","year":"1948","journal-title":"Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales"},{"issue":"4","key":"10.1016\/bs.acr.2025.12.006_bib72","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities","volume":"51","author":"Martin","year":"2019","journal-title":"Nature Genetics"},{"issue":"10","key":"10.1016\/bs.acr.2025.12.006_bib73","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.3390\/cancers12102825","article-title":"Extracellular vesicles as biomarkers in cancer immunotherapy","volume":"12","author":"Mathew","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/bs.acr.2025.12.006_bib74","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: Past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"7471","key":"10.1016\/bs.acr.2025.12.006_bib75","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature12564","article-title":"Criteria for the use of omics-based predictors in clinical trials","volume":"502","author":"McShane","year":"2013","journal-title":"Nature"},{"issue":"16","key":"10.1016\/bs.acr.2025.12.006_bib76","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of american pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/bs.acr.2025.12.006_bib77","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11948-015-9652-2","article-title":"The ethics of big data: Current and foreseeable issues in biomedical contexts","volume":"22","author":"Mittelstadt","year":"2016","journal-title":"Science and Engineering Ethics"},{"issue":"12","key":"10.1016\/bs.acr.2025.12.006_bib78","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: Circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discovery"},{"issue":"01","key":"10.1016\/bs.acr.2025.12.006_bib79","doi-asserted-by":"crossref","first-page":"003","DOI":"10.1055\/s-0034-1397344","article-title":"Overview of MicroRNA biology","volume":"35","author":"Mohr","year":"2015","journal-title":"Seminars in Liver Disease"},{"issue":"7","key":"10.1016\/bs.acr.2025.12.006_bib80","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/bs.acr.2025.12.006_bib81","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41587-019-0392-8","article-title":"Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas","volume":"38","author":"Moncada","year":"2020","journal-title":"Nature Biotechnology"},{"issue":"11","key":"10.1016\/bs.acr.2025.12.006_bib82","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO precision medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-020-00515-y","article-title":"Potential roles and prognostic significance of exosomes in cancer drug resistance","volume":"11","author":"Mostafazadeh","year":"2021","journal-title":"Cell & Bioscience"},{"issue":"2","key":"10.1016\/bs.acr.2025.12.006_bib84","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"Eau-eanm-estro-esur-siog guidelines on prostate cancer\u20142020 update. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"European Urology"},{"issue":"2","key":"10.1016\/bs.acr.2025.12.006_bib85","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. preventive services task force recommendation statement","volume":"157","author":"Moyer","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"6464","key":"10.1016\/bs.acr.2025.12.006_bib86","first-page":"447","article-title":"Dissecting racial bias in an algorithm used to manage the health of populations","volume":"366","author":"Obermeyer","year":"2019","journal-title":"Science (1979)"},{"issue":"29","key":"10.1016\/bs.acr.2025.12.006_bib87","doi-asserted-by":"crossref","first-page":"45042","DOI":"10.18632\/oncotarget.8648","article-title":"Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies","volume":"7","author":"Oca\u00f1a","year":"2016","journal-title":"Oncotarget"},{"issue":"28","key":"10.1016\/bs.acr.2025.12.006_bib88","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non\u2013small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"27","key":"10.1016\/bs.acr.2025.12.006_bib89","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/bs.acr.2025.12.006_bib90","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/MPA.0b013e31823c9d21","article-title":"A review on the role of MicroRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma","volume":"41","author":"Papaconstantinou","year":"2012","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/bs.acr.2025.12.006_bib91","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer","volume":"68","author":"Parekh","year":"2015","journal-title":"European Urology"},{"issue":"7","key":"10.1016\/bs.acr.2025.12.006_bib92","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3748\/wjg.v17.i7.817","article-title":"MicroRNAs in pancreatic ductal adenocarcinoma","volume":"17","author":"Park","year":"2011","journal-title":"World Journal of Gastroenterology: WJG"},{"issue":"2","key":"10.1016\/bs.acr.2025.12.006_bib93","doi-asserted-by":"crossref","first-page":"59","DOI":"10.12793\/tcp.2019.27.2.59","article-title":"A review of computational drug repurposing","volume":"27","author":"Park","year":"2019","journal-title":"Transl Clin Pharmacol"},{"issue":"2","key":"10.1016\/bs.acr.2025.12.006_bib94","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1158\/1078-0432.CCR-16-1543","article-title":"Individualized molecular analyses guide efforts (IMAGE): A prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer","volume":"23","author":"Parsons","year":"2017","journal-title":"Clinical Cancer Research"},{"issue":"18","key":"10.1016\/bs.acr.2025.12.006_bib95","doi-asserted-by":"crossref","first-page":"10639","DOI":"10.3390\/ijms231810639","article-title":"Salivary exosomal miRNA-1307-5p predicts disease aggressiveness and poor prognosis in oral squamous cell carcinoma patients","volume":"23","author":"Patel","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"14","key":"10.1016\/bs.acr.2025.12.006_bib96","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/93.14.1054","article-title":"Phases of biomarker development for early detection of cancer","volume":"93","author":"Pepe","year":"2001","journal-title":"JNCI Journal of the National Cancer Institute"},{"issue":"15","key":"10.1016\/bs.acr.2025.12.006_bib97","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/sj.onc.1210302","article-title":"TP53 mutations in human cancerS: Functional selection and impact on cancer prognosis and outcomes","volume":"26","author":"Petitjean","year":"2007","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/bs.acr.2025.12.006_bib98","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"The Lancet Oncology"},{"issue":"7624","key":"10.1016\/bs.acr.2025.12.006_bib99","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/538161a","article-title":"Genomics is failing on diversity","volume":"538","author":"Popejoy","year":"2016","journal-title":"Nature"},{"issue":"7329","key":"10.1016\/bs.acr.2025.12.006_bib100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/469156a","article-title":"Bring on the biomarkers","volume":"469","author":"Poste","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib101","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/srep00318","article-title":"Towards the understanding of microRNA and environmental factor interactions and their relationships to human diseases","volume":"2","author":"Qiu","year":"2012","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/bs.acr.2025.12.006_bib102","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s43018-020-0047-1","article-title":"Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors","volume":"1","author":"Razavi","year":"2020","journal-title":"Nature Cancer"},{"issue":"5","key":"10.1016\/bs.acr.2025.12.006_bib103","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/humu.23406","article-title":"Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations","volume":"39","author":"Rebbeck","year":"2018","journal-title":"Human Mutation"},{"issue":"19","key":"10.1016\/bs.acr.2025.12.006_bib104","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/bs.acr.2025.12.006_bib105","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncology"},{"issue":"10","key":"10.1016\/bs.acr.2025.12.006_bib106","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: A consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib107","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000231984","article-title":"Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma","volume":"10","author":"Ryu","year":"2010","journal-title":"Pancreatology"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib108","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-genom-090413-025552","article-title":"Translating genomics for precision cancer medicine","volume":"15","author":"Sameek","year":"2014","journal-title":"Annual Review of Genomics and Human Genetics"},{"issue":"10","key":"10.1016\/bs.acr.2025.12.006_bib109","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jtho.2016.05.034","article-title":"Exosomal proteins as diagnostic biomarkers in lung cancer","volume":"11","author":"Sandfeld-Paulsen","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"issue":"6","key":"10.1016\/bs.acr.2025.12.006_bib110","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"The Lancet Oncology"},{"issue":"7","key":"10.1016\/bs.acr.2025.12.006_bib111","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nature Medicine"},{"issue":"7187","key":"10.1016\/bs.acr.2025.12.006_bib112","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature06913","article-title":"The cancer biomarker problem","volume":"452","author":"Sawyers","year":"2008","journal-title":"Nature"},{"issue":"4","key":"10.1016\/bs.acr.2025.12.006_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002286","article-title":"Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study","volume":"14","author":"Sch\u00fctz","year":"2017","journal-title":"PLoS Medicine"},{"issue":"6","key":"10.1016\/bs.acr.2025.12.006_bib114","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nature Reviews. Cancer"},{"issue":"7732","key":"10.1016\/bs.acr.2025.12.006_bib115","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","article-title":"Sensitive tumor detection and classification using plasma cell-free DNA methylomes","volume":"563","author":"Shen","year":"2018","journal-title":"Nature"},{"issue":"21","key":"10.1016\/bs.acr.2025.12.006_bib116","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1001\/jama.2018.17163","article-title":"Clinical decision support in the era of artificial intelligence","volume":"320","author":"Shortliffe","year":"2018","journal-title":"JAMA: the Journal of the American Medical Association"},{"issue":"21","key":"10.1016\/bs.acr.2025.12.006_bib117","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jnci\/djp335","article-title":"Use of archived specimens in evaluation of prognostic and predictive biomarkers","volume":"101","author":"Simon","year":"2009","journal-title":"JNCI Journal of the National Cancer Institute"},{"issue":"7","key":"10.1016\/bs.acr.2025.12.006_bib118","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nature Medicine"},{"issue":"10","key":"10.1016\/bs.acr.2025.12.006_bib119","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/annonc\/mdz227","article-title":"How liquid biopsies can change clinical practice in oncology","volume":"30","author":"Siravegna","year":"2019","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1016\/bs.acr.2025.12.006_bib120","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1016\/bs.acr.2025.12.006_bib121","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1\u20132","key":"10.1016\/bs.acr.2025.12.006_bib122","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0009-8981(01)00665-9","article-title":"About the possible origin and mechanism of circulating DNA","volume":"313","author":"Stroun","year":"2001","journal-title":"Clinica Chimica Acta"},{"issue":"3","key":"10.1016\/bs.acr.2025.12.006_bib123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Medicine"},{"issue":"6","key":"10.1016\/bs.acr.2025.12.006_bib124","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/cr.2014.44","article-title":"Double-stranded DNA in exosomes: A novel biomarker in cancer detection","volume":"24","author":"Thakur","year":"2014","journal-title":"Cell Research"},{"issue":"8","key":"10.1016\/bs.acr.2025.12.006_bib125","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/annonc\/mdv177","article-title":"Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer","volume":"26","author":"Tie","year":"2015","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib126","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev-cancerbio-030518-055609","article-title":"Deciphering human tumor biology by single-cell expression profiling","volume":"3","author":"Tirosh","year":"2019","journal-title":"Annual Review of Cancer Biology"},{"issue":"5748","key":"10.1016\/bs.acr.2025.12.006_bib127","first-page":"644","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science (1979)"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: The convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nature Medicine"},{"issue":"25","key":"10.1016\/bs.acr.2025.12.006_bib129","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/bs.acr.2025.12.006_bib130","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1016\/bs.acr.2025.12.006_bib131","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ccell.2019.09.003","article-title":"Toward the early detection of cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA","volume":"36","author":"van der Pol","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.acr.2025.12.006_bib132","first-page":"1186","article-title":"Enhancing the IDEAS framework with ontology: Designing digital interventions for improving cancer patients\u2019 wellbeing","volume":"2021","author":"Veggiotti","year":"2021","journal-title":"AMIA \u2026 Annual"},{"issue":"1","key":"10.1016\/bs.acr.2025.12.006_bib133","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00784-021-03995-5","article-title":"Radiotherapy changes the salivary proteome in head and neck cancer patients: Evaluation before, during, and after treatment","volume":"26","author":"Ventura","year":"2022","journal-title":"Clinical Oral Investigations"},{"key":"10.1016\/bs.acr.2025.12.006_bib134","series-title":"The EU general data protection regulation (GDPR)","author":"Voigt","year":"2017"},{"issue":"4","key":"10.1016\/bs.acr.2025.12.006_bib135","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: Towards implementation of circulating tumor DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nature Reviews. Cancer"},{"issue":"48","key":"10.1016\/bs.acr.2025.12.006_bib136","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017990","article-title":"NY-ESO-1 expression in solid tumors predicts prognosis","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/bs.acr.2025.12.006_bib137","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1158\/1940-6207.CAPR-09-0094","article-title":"MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease","volume":"2","author":"Wang","year":"2009","journal-title":"Cancer Prevention Research"},{"issue":"11","key":"10.1016\/bs.acr.2025.12.006_bib138","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1373\/clinchem.2010.147405","article-title":"The MicroRNA spectrum in 12 body fluids","volume":"56","author":"Weber","year":"2010","journal-title":"Clinical Chemistry"},{"issue":"6","key":"10.1016\/bs.acr.2025.12.006_bib139","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131403","article-title":"PD-L1 and survival in solid tumors: A meta-analysis","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/bs.acr.2025.12.006_bib140","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx118","article-title":"Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer","volume":"109","author":"Wyatt","year":"2017","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"11","key":"10.1016\/bs.acr.2025.12.006_bib141","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1039\/C4MB00353E","article-title":"Prioritizing candidate disease miRNAs by integrating phenotype associations of multiple diseases with matched miRNA and mRNA expression profiles","volume":"10","author":"Xu","year":"2014","journal-title":"Molecular Biosystems"},{"issue":"2","key":"10.1016\/bs.acr.2025.12.006_bib142","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: Prognostic and predictive potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"The Lancet Oncology"},{"issue":"7518","key":"10.1016\/bs.acr.2025.12.006_bib143","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature13438","article-title":"Proteogenomic characterization of human colon and rectal cancer","volume":"513","author":"Zhang","year":"2014","journal-title":"Nature"},{"issue":"0","key":"10.1016\/bs.acr.2025.12.006_bib144","doi-asserted-by":"crossref","first-page":"bar026","DOI":"10.1093\/database\/bar026","article-title":"International cancer genome consortium data portal--a one-stop shop for cancer genomics data","volume":"2011","author":"Zhang","year":"2011","journal-title":"Database"},{"issue":"3","key":"10.1016\/bs.acr.2025.12.006_bib145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41591-018-0334-x","article-title":"Non-invasive prenatal sequencing for multiple mendelian monogenic disorders using circulating cell-free fetal DNA","volume":"25","author":"Zhang","year":"2019","journal-title":"Nature Medicine"},{"issue":"12","key":"10.1016\/bs.acr.2025.12.006_bib146","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discovery"},{"issue":"48","key":"10.1016\/bs.acr.2025.12.006_bib147","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"}],"container-title":["Advances in Cancer Research","Biomarkers for Cancer Screening, Diagnosis and Targeted Therapeutic Approaches"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X25000958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X25000958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:26:59Z","timestamp":1779298019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X25000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443432729"],"references-count":147,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2025.12.006","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}